Extended trial tests drug to control rare childhood blood sugar disorder

NCT ID NCT03941236

Ongoing Disease control Sponsor: Zealand Pharma Source: ClinicalTrials.gov ↗

Summary

This study is following children with congenital hyperinsulinism (CHI) to see how safe and effective the drug dasiglucagon is over a long period. CHI causes dangerously low blood sugar. The drug is given as a continuous infusion under the skin. The main goal is to monitor side effects while also seeing if it helps reduce the need for other treatments like feeding tubes or surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alder Hey Children's Hospital NHS Foundation Trust

Liverpool, United Kingdom
Children's Hospital Colorado

Aurora, Colorado, 80045-7106, United States
Cook Children's Endocrinology and Diabetes Clinic

Fort Worth, Texas, 76104-2710, United States
Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom
Hadassah Medical Center

Jerusalem, 9765422, Israel
Manchester University NHS Foundation Trust

Manchester, United Kingdom
NHS Greater Glasgow and Clyde

Glasgow, United Kingdom
Otto von Guericke University Magdeburg, Department of Pediatrics

Magdeburg, 39120, Germany
The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
University Hospital Düsseldorf, Department of Pediatrics

Düsseldorf, 40225, Germany

Conditions

Explore the condition pages connected to this study.

CONGENITAL HYPERINSULINISM